[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bladder-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bladder-dysfunction":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,46,85,111,137,164,186,212,246],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100636829","impact-of-dialysis-duration-and-diuresis-on-bladder-capacity-and-compliance-in-end-stage-renal-disease-patients-awaiting-renal-transplant-100636829",false,"NCT07570771","IMPACT OF DIALYSIS DURATION AND DIURESIS ON BLADDER CAPACITY AND COMPLIANCE IN END STAGE RENAL DISEASE PATIENTS AWAITING RENAL TRANSPLANT","ESRD","Inclusion Criteria:\n\n* Patients aged 18-65 years diagnosed with end-stage renal disease (ESRD)\n* Patients on maintenance dialysis for a duration of 6 to 24 months\n* ESRD secondary to non-urological causes\n* Patients awaiting renal transplantation\n\nExclusion Criteria:\n\n* Patients with diabetes mellitus\n* Patients with neurogenic bladder\n* Patients with prior urological surgeries\n* Patients with active urinary tract infection\n* Patients with pre-existing lower urinary tract symptoms before dialysis\n* Patients on medications affecting lower urinary tract function\n* Patients with neurological or systemic diseases affecting bladder function","ALL","18 Years","65 Years",{"count":20,"type":21},87,"ESTIMATED","01 Weeks","OBSERVATIONAL","Patients with end-stage renal disease (ESRD) who are on dialysis for a long time may experience bladder problems as their urine output decreases and normal bladder filling is lacking. As a result, bladder capacity may be reduced and compliance may deteriorate, which can impact the success of kidney transplantation.\n\nOur prospective observational study is designed to investigate how dialysis duration and residual urine output (diuresis) influence bladder capacity and compliance in ESRD patients who are waiting for kidney transplantation. The adult patients undergoing regular dialysis will be assessed clinically, and they will also be subjected to laboratory tests, imaging, and urodynamic studies.\n\nThrough this study, we aim to determine the frequency of bladder malfunction and its correlation with the length of dialysis and the amount of urine excretion. The results might enhance the pre-transplant workup and offer a basis for urological post-transplantation management that could minimize complications.",[26,27],"End-Stage Renal Disease Requiring Haemodialysis","Bladder Dysfunction",[29,30,31,32],"Dialysis Duration","Bladder Capacity","Bladder Compliance","Renal Transplant Candidates","RECRUITING","2026-04-29",{"date":36,"type":37},"2026-05-06","ACTUAL",{"date":39,"type":37},"2026-02-02",{"date":41,"type":21},"2027-02",{"name":43,"class":44},"Sindh Institute of Urology and Transplantation","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":69,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100410565","early-phase-1-concomitant-renal-and-urinary-bladder-allograft-transplantation-100410565","NCT04626167","Concomitant Renal and Urinary Bladder Allograft Transplantation","Inclusion Criteria:\n\n* Male or female patients between 1 yr. and 60 years of age.\n* Subject is willing and able to give signed informed consent, or have a legally authorized representative who is willing and able to give consent. Informed assent will be required for children 6-17 years of age as appropriate or warranted.\n* Patients with CKD secondary to neurogenic bladder, lower urinary tract obstruction or other disorders of the urinary bladder.\n* Medical need for a bladder transplant, as defined by the presence of exhibiting \"hostile bladders\" defined as end filling pressure or detrusor leak point pressure (DLPP) of or greater than 40 cm H20 or at below estimated bladder capacity for age, or detrusor overactivity with detrusor sphincter dyssynergia, or new onset of upper urinary tract changes (hydronephrosis, vesicoureteral reflux) in the last 12 months\n* If a concomitant kidney transplant is being considered, additionally, estimated GFR less than or equal to 20 mL\u002Fmin or dialysis. If GFR 20-25 mL\u002Fmin would also qualify if expected progression is rapid (\\>10 mL\u002Fmin\u002Fyear)\n* Vetting and approval by the Mayo Clinic multidisciplinary transplant team (MDC) for renal transplantation.\n* Ability of subject and\u002For care provider to be successfully trained in clean intermittent catheterization and bladder cycling. Or current use of CIC.\n* Utilization of maximally-tolerated dose and regimen of medical therapy (e.g. anticholinergics) or failure to tolerate\u002Fcontraindications to such agents.\n* Psychosocial clearance: Demonstrated commitment to psychological evaluation perioperatively, in which the psychologist must confirm that the subject has the maturity and stable psychosocial environment necessary for this research study.\n* Agree to avoid pregnancy for 1 year after surgery through abstinence or approved contraception as noted in Appendix A (female subjects only)\n* If patient has a history of malignancy (with the exception of localized non-melanoma skin cancer) the patient must be at least 5 years from termination of treatment without evidence of recurrent disease.\n\nExclusion Criteria:\n\n* They are pregnant or breastfeeding, or planning a pregnancy during the course of the study, or who are of child bearing potential and not willing to continue using an effective method of birth control (i.e. with a low failure rate of less than 1 percent per year including injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence, or a vasectomized partner), or\n* Any contraindication to general anesthesia or evaluation reveals that the subject cannot safely undergo general anesthesia and post-operative recovery due to severe cardiovascular, pulmonary, neurological, metabolic, or rheumatologic disease (requires special consultation)\n* Any contraindication or known anaphylactic or severe systemic reaction to either human blood products or materials of bovine origin\n* Subjects with a current positive (\\>=5 mm induration for high-risk subjects; otherwise \\>=10 mm of induration) purified protein derivative (PPD) test are excluded unless they have completed a full course of treatment for latent TB and have a negative chest x-ray film at enrollment.\n* Known history of hypersensitivity to aminoglycosides or fluoroquinolones\n* Use of any investigational product within 3 months\n* Prior participation in the study\n* Currently smoking\n* Current incarceration for any reason\n* Unwillingness, inability, or unlikely compliance of individual and\u002For primary caregiver with study related schedules procedures, management, or follow -up in the opinion of the PI and\u002For co-investigators\n* Any circumstance in which the investigator deems participation in the study is not in the subject's best interest\n* Subjects with an ALT or AST value \\>3 times the upper limit of normal\n* Subjects with acute or chronic abdominal skin infections and\u002For acute or chronic abdominal inflammatory conditions such as inflammatory bowel disease\n* Subjects with uncontrolled diabetes defined as HgA1c\\>10, unstable cardiac and\u002For pulmonary disorders, or bleeding disorders\n* Active malignant neoplasm (with the exception of localized non-melanoma skin cancer) that is untreated, unresponsive to available treatment, or too recently treated to determine relapse risk.\n* Surgical procedure for transplantation cannot be successfully performed for anatomical reasons\n* Life expectancy with successful transplantation is estimated to be \\\u003C5 years for any reason.\n* There is any other disease, physical examination finding, or clinical laboratory result that provides a reasonable suspicion of a disease or condition that contraindicates the procedure or the interpretation of results or render the subject at high risk for treatment complications, or\n* Serious or uncontrolled psychiatric illness or disorder that could compromise their understanding of, or compliance with, follow-up visits\u002Fcare after transplant, or\n* Taking medications on specified hourly intervals that may be affected by changes to renal clearance, or\n* Hypertension stage II \\> 99th percentile, unless they had a complete workup to exclude secondary etiologies other than being overweight, or\n* Presence of severe coagulopathy, (hyper or hypo)\n* Patient is not up to date on current CDC recommended vaccines","1 Year","60 Years",{"count":55,"type":21},30,"INTERVENTIONAL",[58],"EARLY_PHASE1","The purpose of this study is to establish if concomitant renal and vascularized urinary bladder allograft transplantation is feasible.",[61,27,62,63,64,65,66,67,68],"Chronic Kidney Diseases","Bladder Absence","Posterior Urethral Valve","Neurogenic Bladder","Bladder Exstrophy","Bladder Outlet Obstruction","Failure, Kidney","Transplant",[70,71,72,73,74],"Urinary Bladder Transplant","Bladder Transplant","Bladder Augment","Neobladder","Ileocystoplasty","2026-04-20",{"date":77,"type":37},"2026-04-23",{"date":79,"type":37},"2021-06-01",{"date":81,"type":21},"2026-08",{"name":83,"class":44},"Mayo Clinic",2,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":95,"conditions":96,"keywords":99,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":45},"100489354","noninvasive-ultrasound-assessment-of-detrusor-dysfunction-100489354","NCT05652023","Noninvasive Ultrasound Assessment of Detrusor Dysfunction","NUADD","Inclusion Criteria:\n\n* Aim1:\n\nAge \\>18 scheduled to undergo UDS for their clinical care for one of the included diagnoses.\n\n-Aim2: Inclusions: Age \\>45 scheduled to undergo selective photovaporization of the prostate.\n\nExclusion Criteria:\n\n* Aim1:Obesity (BMI \\>35kg\u002Fm2), known neurologic disease impacting bladder function (e.g. spinal cord injury, multiple sclerosis, Parkinson's, prior cerebrovascular accident), previous pelvic radiation therapy, previous radical pelvic surgery (such as for uterine or colorectal cancer), prior bladder surgery (including prostate resection), and pregnant or breast-feeding women.\n* Aim2:Obesity (BMI \\>35kg\u002Fm2), known neurologic disease impacting bladder function (e.g. spinal cord injury, multiple sclerosis, Parkinson's, prior cerebrovascular accident), previous pelvic radiation therapy, previous radical pelvic surgery (such as colorectal cancer).","90 Years",{"count":94,"type":21},2023,"The purpose of this study is to test a new ultrasound method called Quantitative Ultrasound Bladder Vibrometry to detect abnormal bladder function.",[27,97,98],"Overactive Bladder","BPH With Urinary Obstruction",[100,31,101,102],"Detrusor Pressure","Ultrasound","Ultrasound Vibrometery","2026-03-23",{"date":105,"type":37},"2026-03-27",{"date":107,"type":37},"2023-04-20",{"date":109,"type":21},"2028-12-20",{"name":83,"class":44},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":120,"conditions":121,"keywords":124,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":45},"100627628","exploring-clinical-utility-of-wearables-for-the-bladder-in-pelvic-health-physical-therapy-clinics-100627628","NCT07451106","Exploring Clinical Utility of Wearables for the Bladder in Pelvic Health Physical Therapy Clinics","ClinicWeB","Inclusion Criteria:\n\n* Referral for pelvic health physical therapy\n* 18 years of age or older\n* Postpartum women: 8 or more weeks postpartum, manual muscle test greater than or equal to 2\u002F5 pelvic floor muscle strength via Modified Oxford Scale\n* Men: status post radical prostatectomy after catheter removal\n\nExclusion Criteria:\n\n* cognitive, dexterity or visual impairment so severe that it precludes use of the neurotechnology tool or ability to use a smartphone\n* Postpartum women: any unhealed tears from childbirth, active vaginal infection or unresolved uterine bleeding, currently pregnant, have seen a pelvic health physical therapist in the past 3 months\n* Men: status post another surgery related to prostate, catheter placement more than 1 week after radical prostatectomy, post-op infection",{"count":119,"type":21},25,"Pelvic health physical therapy (PHPT) is an evidence-based intervention for bladder dysfunction (BD) and pelvic floor disorders (PFD) in men postprostatectomy, and postpartum women. However, there is a dearth of objective outcome measures - in particular, those that can capture changes remotely, between clinic visits. In other domains, such as physical activity, wearable digital devices have started to fill this gap. The investigators aim to evaluate if commercially available wearables for the bladder (WeB) can provide valid, objective outcomes to evaluate, monitor and treat people with BD and PFD. The WeB toolkit, comprising a wearable bladder ultrasound device and an intravaginal exerciser (women only), eventually aims to provide real-world, actionable data to both users and healthcare providers, thereby improving patient outcomes through closed-loop interventions. Preliminary studies in women with multiple sclerosis have shown strong associations with gold-standard clinical measures, suggesting that WeB tools could revolutionize care for these patients. However, the effectiveness of these tools in a wider range of patient demographics, especially postpartum women, and men, has yet to be established. The investigators seeks to extend the promising pilot findings to these additional 'special' populations seen in the PHPT clinic. The investigators hypothesize that the WeB tools will retain their accuracy and utility across these diverse groups. The investigators plan to i) validate WeB in these special populations against gold-standard clinical measures for BD, ii) evaluate the responsiveness of WeB tools to changes in outcomes before and after PHPT and iii) assess user experience in these populations. By ensuring the WeB tools' broad applicability, this research seeks to close the gap in continuous care and enable objective, personalized treatment strategies. The outcomes will have significant implications for the management of BD and PFD, potentially offering a more inclusive and empowering approach to patient care in women postpartum and men post-prostatectomy.",[122,123,27],"Postpartum Bladder Dysfunction","Post-prostatectomy Bladder Dysfunction",[125,126,127],"bladder dysfunction","pelvic health physical therapy","wearables","2026-02-27",{"date":130,"type":37},"2026-03-05",{"date":132,"type":37},"2024-07-11",{"date":134,"type":21},"2026-07",{"name":136,"class":44},"University of California, San Francisco",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":56,"phases":147,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":45},"100620298","define-final-selection-choice-criteria-for-a-coloplast-catheter-ensuring-highest-patient-satisfaction-via-surveys-eva-100620298","NCT07355803","Define Final Selection Choice Criteria for a Coloplast Catheter Ensuring Highest Patient Satisfaction Via Surveys (EVA).","EVA-study on Catheter Selection Criteria at Start of Self-catheterization","EVA","Inclusion Criteria:\n\n* Female or male aged eighteen years or older;\n* Written informed consent;\n* Subject affiliated with a social security scheme or beneficiary;\n* Subject with neurogenic or non-neurogenic bladder issues, justifying the implementation of intermittent self-catheterisation (ISC) to clean out the bladder;\n* Subject who received his\u002Fher initial ISC training at the time of inclusion;\n* Subject for whom the expected ISC duration is at least six months;\n* Subject for whom at least two types of Coloplast catheters have been introduced and who has chosen to use Coloplast catheters as the first catheter for self-catheterisation;\n* Subject able to independently conduct ISC;\n* Subject for whom the healthcare professional has recommended to conduct ISC at least four times per day.\n\nExclusion Criteria:\n\n* Vulnerable subject with regard to the current regulation:\n\n  * Pregnant, parturient or breast-feeding woman;\n  * Subject deprived of freedom by judicial, medical or administrative decision;\n  * Underage subject;\n  * Subject is legally protected or unable to express his\u002Fher consent;\n  * Subject not affiliated with or not a beneficiary of a social security scheme;\n  * Subject falling into several categories above;\n* Subject who refused to participate in the study;\n* Subject participating in an interventional clinical study;\n* Subject who, according to the investigator, has cognitive problems that prevent him\u002Fher from completing a questionnaire or for whom the assessment may be a problem.",{"count":146,"type":21},107,[148],"NA","Understanding the Coloplast Intermittent Catheter Selection Study:\n\nThis study aims to understand how adults who need to use catheters to empty their bladder by themselves decide which Coloplast catheter works best for them. The two types of catheters studied are called SpeediCath and Luja.\n\nWhy is this study being done? The study wants to find out which catheter type helps people feel most satisfied when they start to use it on their own. It also looks at why people choose their catheter at the beginning, how happy they are with it over the first six months, and what problems they might face using it.\n\nWho can join the study?\n\n* Adults aged 18 or older who have bladder problems and need to empty their bladder using a catheter.\n* People who have been trained on how to use a catheter.\n* People who have chosen to use either SpeediCath or Luja catheters from Coloplast.\n* People who can perform the catheterization themselves at least two times per day.\n\nCertain people cannot join, such as pregnant women, anyone who cannot give consent, or those who have trouble filling out questionnaires.\n\nWhat will happen in the study?\n\nParticipants will visit the study center three times:\n\n* At the start (to select their catheter and answer questions about the reasons for the specific catheter selection)\n* After 3 to 12 weeks (to share their perception on the impact of the used catheter)\n* After 6 months (to measure final satisfaction and any difficulties)\n\nIf a participant changes to a different catheter type or catheter brand during the study, this will be recorded, and they will continue in the study.\n\nHow will this study help? The information gathered will help healthcare providers understand what matters most to people when selecting a catheter. This can improve how catheters are recommended and support patients better during self-catheterization and improve treatment adherence and compliance.",[151,152,27,153],"Neurogenic Bladder Disorder","Non-Neurogenic Bladder","Urinary Retention","2026-01-13",{"date":156,"type":37},"2026-01-21",{"date":158,"type":37},"2025-10-21",{"date":160,"type":21},"2026-10-28",{"name":162,"class":163},"Coloplast NV\u002FSA","INDUSTRY",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":170,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":45},"100438790","impact-of-chemotherapy-on-urinary-biomarkers-and-non-invasive-urodynamics-in-children-100438790","NCT04993859","Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children","Inclusion Criteria:\n\n* Children aged 5-13 years old\n* A history of cancer\n* Treatment with a chemotherapy regimen including VCR and\u002For DOX\n* Completion of chemotherapy at least one year prior to study enrollment and survey completion.\n\nExclusion Criteria:\n\n* Patients with a:\n* Primary pelvic tumor\n* Pelvic irradiation\n* Pre-existing bladder\u002Fbowel dysfunction\n* Spinal defects\n* Neurologic disorder\n* Neuro-oncologic tumor or brain metastasis\n* Cyclophosphamide or ifosfamide therapy","5 Years","13 Years",{"count":173,"type":21},152,"The over-arching aim of this study is to evaluate the effects of two specific anti-cancer chemotherapies, vincristine and doxorubicin, on bladder function and urine composition.",[176,27],"Survivors of Childhood Cancer","2025-10-13",{"date":179,"type":37},"2025-10-15",{"date":181,"type":37},"2021-06-02",{"date":183,"type":21},"2026-07-09",{"name":185,"class":44},"University of Colorado, Denver",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":56,"phases":195,"briefSummary":196,"conditions":197,"keywords":198,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":45},"100594450","nesa-neuromodulation-versus-transcutaneous-posterior-tibial-stimulation-100594450","NCT07019597","NESA Neuromodulation Versus Transcutaneous Posterior Tibial Stimulation","Non-invasive NESA Neuromodulation Versus Transcutaneous Posterior Tibial Nerve Stimulation for the Treatment of Overactive Bladder","NesaTibial","Inclusion Criteria:\n\n* Minimum criteria for a primary diagnosis of overactive bladder who have or have not received active\u002Falternative treatments for this pathology.\n* Patients with previous pharmacological treatments that have not obtained an adequate clinical response.\n* Patients whose cognitive abilities are competent to participate in the study and are able to complete the study questionnaires and have given written consent to participate in the study.\n* Without further contraindications for electrotherapy treatment such as serious use of pacemakers, pregnancy, internal bleeding, poor skin condition (ulcerations, wounds...) and\u002For phobia of electricity.\n\nExclusion Criteria:\n\n* Presence of urinary fistula.\n* Infections in the last 12 months.\n* Haematuria during the trial period.\n* Pregnancy or plans to become pregnant during the study.\n* Pathology of the central or peripheral nervous system (multiple sclerosis, Parkinson's disease, etc.).\n* Uncontrolled diabetes.\n* Currently treated with Botox injections for the bladder or within the last year.\n* Current treatment with interstim or currently implanted interstim device.\n* Bladder outlet obstruction.\n* Urinary retention.\n* Treatment with more than two antidepressants and\u002For multiple benzodiazepines, as well as antiepileptics.\n* Contraindications for electrotherapy treatment.",{"count":119,"type":21},[148],"Introduction: Overactive bladder (OAB) is a common condition characterized by urinary urgency, frequency, and, in some cases, urge incontinence. Non-invasive neuromodulation has emerged as an effective therapeutic option by modulating the neural pathways involved in bladder control. This approach offers a promising alternative for patients who do not respond to conventional treatments.\n\nObjectives: To evaluate the effect of non-invasive NESA neuromodulation compared to posterior tibial stimulation in patients with overactive bladder.\n\ncompared to posterior tibial stimulation, with same-day exercises and patient education on quality of life, symptoms, discomfort and sleep.\n\nday of the session and patient education on quality of life, symptoms, discomfort and sleep.\n\nMethods: Twenty-four patients (24 women), aged 38-85 years with overactive bladder will be included in this experimental clinical trial study. Each patient will attend ten sessions two days a week. Patient life quality will be measured using SF-36, sleep quality with the Pittsburgh questionnaire, perception of urinari incontinence (UI) symptoms and patient quality of life with the ICIQ-SF questionnaire. All these variables will be measured before, immediately after the ten sessions and at two months after the end of treatment.\n\nEthic: The study was approved by the ethics committee of the University of Valencia, and all participants will be given an informed consent form.",[27],[199,200,201,202],"overactive bladder","Transcutaneous neuromodulation","Nesa Non-Invasive Neuromodulation","Posterior tibial nerve stimulation","2025-06-10",{"date":205,"type":37},"2025-06-13",{"date":207,"type":37},"2025-05-01",{"date":209,"type":21},"2025-09-01",{"name":211,"class":44},"Daniel David Álamo Arce",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":220,"minAge":221,"maxAge":222,"enrollmentInfo":223,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":225,"conditions":226,"keywords":232,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":244,"locationsCount":45},"100549884","study-of-the-quality-of-life-in-school-aged-children-with-posterior-urethral-valves-100549884","NCT06439862","Study of the Quality of Life in School Aged-children With Posterior Urethral Valves","Quality of Life in School Aged-children With Posterior Urethral Valves","QUALIVUP","Inclusion Criteria:\n\n* Male patients and their parents\u002Frelatives\n* Aged 6 to 17 years old\n* Treated for PUV in their first year of life between 2006 and 2018\n* Managed in the Femme-Mère-Enfant Hospital in Lyon\n\nExclusion Criteria:\n\n* Children with pre-existing severe cognitive and physical disability (physician's rating) from other condition\n* Children enable to complete QoL questionnaire due to mental or communication impairment","MALE","6 Years","17 Years",{"count":224,"type":21},300,"Posterior urethral valves (PUV) are the most common congenital obstructive lesion of the urethra, affecting from 1 per 3000 to 1 per 8000 live births. Valve ablation usually resolves the obstruction in PUV but patients still may suffer of deterioration in renal and urinary functions.\n\nRenal insufficiency is the most feared long-term complication. Up to 50 % of the patients will develop chronic kidney disease (CKD), and up to 20 % will develop end-stage renal disease (ESRD) and ultimately will require kidney transplantation. PUV is the first urological cause of ESRD. Progression towards CKD depends on febrile urinary tract infections (UTIs), severity of a vesicoureteral reflux and bladder dysfunction.\n\nBladder dysfunction is due to an overactive and small poorly compliant bladder during infancy. Detrusor overactivity usually decreases in childhood and bladder capacity increases. The most common symptom of this bladder dysfunction is urinary incontinence. 60 % of children are continent at the age of 5 years old and 90 % at 10 years old. In case of persistent bladder dysfunction, medical treatment (anticholinergics, alpha-blockers) may be introduced, or even intermittent catheterizations.\n\nCurrent scientific literature has very few studies on quality of life (QoL) in patients with PUV, mostly in adult patients and very small cohorts. Men treated for PUV in childhood had a good quality of life compared to the normative population, except for sleeping, eating and sexual activity. It seemed that the more severe the urological and nephrological functions were, the lower the QoL was. Children were only asked about intermittent urinary catheterization, and family point of view has never been collected. However, QoL and long-term evolution represent the first concerns of parents-to-be in prenatal counseling, or after diagnosis in an infant with PUV.\n\nHence, the aim of the study is to investigate the quality of life in school-aged children who had been treated for PUV in their first year of life, as measured by the Pediatric Quality of Life Inventory Version 4.0 (PedsQL 4.0).",[227,63,228,229,230,27,231],"Quality of Life","Renal Insufficiency","Chronic Renal Disease","End Stage Renal Disease","Urinary Incontinence",[233,234,235,236,237],"Quality of life","Posterior Urethral Valves","Children","Adolescents","Family","2025-05-05",{"date":240,"type":37},"2025-05-07",{"date":242,"type":37},"2024-08-20",{"date":81,"type":21},{"name":245,"class":44},"Hospices Civils de Lyon",{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":252,"targetDuration":4,"studyType":56,"phases":254,"briefSummary":255,"conditions":256,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":45},"100552369","the-utility-of-shanfield-implantation-technique-during-creation-of-mitrofanoff-procedure-in-pediatric-age-group-100552369","NCT06472193","The Utility of Shanfield Implantation Technique During Creation of Mitrofanoff Procedure in Pediatric Age Group","Inclusion Criteria:\n\n* children with neurogenic bladder dysfunction, as an alternative route for catheterization for those who are unable or unwilling to utilize the native route being sensate urethra.\n* in cases where bladder neck closure or reconstruction is necessary to achieve continence.\n* Patients with urethral valves, prune belly syndrome and bladder exstrophy, performed either as an isolated procedure enabling patients to perform clean intermittent catheterization (CIC) or in relation with concomitant bladder augmentation\n\nExclusion Criteria:\n\npatients clinically unfit for surgery patients underwent previous traditional Mitroffanof procedure\n\n\\-",{"count":253,"type":21},10,[148],"Management of bladder dysfunction was revolutionized by the introduction of intermittent catheterization by Lapides. Later, Mitrofanoff described a trans-appendicular continent cystostomy, launching a new concept whereby the bladder could be emptied by a route other than the urethra.\n\nClean intermittent catheterization (CIC) is one of the main tools for neurogenic lower urinary tract dysfunction management, as it provides adequate bladder emptying and protects the upper urinary tract from high pressures, hence preventing progressive renal damage.\n\nDespite its important role, CIC is difficult to perform in various situations: lack of manual dexterity, female wheelchair patients, body habitus, anatomical morbidity due to extensive surgery or psychological problems. For such patients, continent urinary diversion (CUD) is a viable option for bladder emptying optimization.\n\nVarious techniques have been described to create an anti-reflux appendicovesical anastomosis in pediatric lower urinary tract reconstruction, whether performed via an extravesical or an intravesical route, all share a common denominator of creating a submucosal tunnel in an attempt to replicate the physiological anti-reflux mechanism.",[27],"2024-06-24",{"date":259,"type":37},"2024-06-26",{"date":261,"type":37},"2024-02-01",{"date":263,"type":21},"2025-08-01",{"name":265,"class":44},"Sohag University"]